FDA ex­pands la­bel for Vi­iV's Cabe­nu­va to cov­er bi-month­ly ad­min­is­tra­tion HIV treat­ment

Adults liv­ing with HIV will now have the op­tion to re­ceive treat­ment just six times a year, as the FDA clears Vi­iV Health­care’s Cabe­nu­va for use every two months.

The la­bel ex­pan­sion comes just a few days af­ter the one-year an­niver­sary of Cabe­nu­va’s ini­tial ap­proval, which marked the his­toric OK for a long-act­ing HIV treat­ment that can be ad­min­is­tered once every month in­stead of dai­ly.

On­ly those who are al­ready vi­ro­log­i­cal­ly sup­pressed, have no his­to­ry of treat­ment fail­ure or sus­pect­ed re­sis­tance to ei­ther of the ac­tive in­gre­di­ents are el­i­gi­ble for this dos­ing reg­i­men.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER